|
|
|
04.07.25 - 10:45
|
Roche Sell (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Roche von 245 auf 246 Franken angehoben, aber die Einstufung auf "Sell" belassen. James Quigley rechnet in seinem am Freitag vorliegenden Ausblick auf den Halbjahresbericht ......
|
|
|
|
|
01.07.25 - 14:03
|
Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer (Business Wire)
|
|
|
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the appointment of Shishir Gadam, Ph.D., as chief technical officer. Dr. Gadam has extensive experience in the biotechnology industry and brings deep expertise and leadership in biologics development and manufacturing to Marea Therapeutics.
Dr. Gadam was most recently chief technical officer at Cargo Therapeutics and responsible for technical operations for the cell therapy portfolio. Prior to Cargo, he held the position of vice president and head of cell therapy global manufacturing sciences & technology at Juno therapeutics, a Celgene company and Bristol Myers Squibb where he was instrumental in launch of two cell therapy commercial CAR-T products. During his tenure at Genetech/Roche from 2006-2018, he held positions of increasing responsibility acr...
|
|
|
01.07.25 - 11:42
|
Roche Buy (DPA-AFX)
|
|
|
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Roche mit Blick auf das dritte Quartal auf "Buy" belassen. Das Interesse der Investoren habe sich zuletzt auf die Medikamente Astegolimab gegen die Lungenkrankheit COPD, Giredestrant ......
|
|
|
|
|
30.06.25 - 08:33
|
Roche Underweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Roche mit einem Kursziel von 220 Franken auf "Underweight" belassen. Mai-Daten des US-Gesundheitsforschungsunternehmens Iqvia hätten ihn zu dem Schluss geführt, dass sich seine Erwartung eines achtprozentigen ......
|
|
|
|
|
30.06.25 - 07:03
|
Changes to the Roche Enlarged Corporate Executive Committee (GlobeNewswire EN)
|
|
|
Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche Pharma Research and Early Development (pRED) and member of the enlarged Corporate Executive Committee will be retiring from Roche. Hans Clevers joined the Roche Board of Directors in 2019 and then was appointed Head of Roche pRED in March 2022....
|
|
|
|
|
27.06.25 - 06:30
|
SENSETIME-W Launches AI Solution for Professional IVD Scenarios (AAStocks)
|
|
|
SENSETIME-W (00020.HK) partnered with Roche Diagnostics to launch an AI solution, "Easy Ask e-Answer (literal translation of "易問e答")", aimed at professional scenarios in IVD (In Vitro Diagnostics). The platform is based on SenseTime's self-developed SenseNova multimodal foundation mod......
|
|
|
|
|
|
|
|
|
|
|
23.06.25 - 07:03
|
Early data suggest Roche′s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A (GlobeNewswire EN)
|
|
|
Basel, 23 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase I/II data on NXT007 in people with haemophilia A, supporting its progression into phase III clinical development. NXT007 is a next-generation investigational bispecific antibody, engineered by Chugai, a member of the Roche Group. Early data from the NXTAGE study suggest that NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A (without factor VIII inhibitors). NXT007 showed a tolerable safety profile with no thromboembolic events reported so far.1 These results were featured as an oral presentation at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress, 21-25 June, Washington D.C., United States.1...
|
|
|
|
|
|
|
|
|
|
|
20.06.25 - 17:48
|
Roche′s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma (GlobeNewswire EN)
|
|
|
Basel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today results from the phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab) administered subcutaneously in combination with Polivy® (polatuzumab vedotin) demonstrated a clinically meaningful and statistically significant improvement in its primary endpoints of progression-free survival (PFS) and objective response rate (ORR) compared to MabThera®/Rituxan® (rituximab), gemcitabine and oxaliplatin (R-GemOx), in people with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who are not eligible for transplant.1 Primary analysis data were featured at the 18th International Conference on Malignant Lymphoma as a late-breaking oral presentation....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
